with global rights
Abbreviations: Immuno-oncology (I/O), B-cell non-Hodgkin lymphoma (B-NHL), relapsed or refractory (r/r), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), neurotrophic tropomyosin receptor kinase (NTRK).
Notes: * denotes Greater China-only trials; ** denotes Greater China trial in preparation or under planning. Greater China = Chinese mainland, Hong Kong, Macau and Taiwan. (1) Also launched in Hong Kong and Macau; (2) Phase 1b/2 study of tebotelimab in combination with ZEJULA in gastric cancer (GC), biliary tract cancer (BTC) and triple negative breast cancer (TNBC); (3) Including non-small cell lung cancer; (4) Commercially available in Hong Kong; (5) Global Ph III trial ongoing; (6) Ph III trial initiated in Greater China; (7) Also approved in Hong Kong and Taiwan; (8) Broad development in both mono and combo therapies; (9) Global Ph II pivotal trial ongoing, also initiated in Greater China; (10) Ph II registrational trial initiated in Greater China; (11) Bridging study met primary endpoint in October 2021; NDA acceptance by the NMPA in January 2022; (12) Global Ph II/III study and registration path in 1L gastric & GEJ cancer; combo with chemo and retifanlimab or tebotelimab; (13) Ph II/III trial initiated in Greater China; (14) Global Ph III trial initiated; (15) Global Ph I/IIa trial ongoing; (16) Ph I POC trial ongoing in Greater China; (17) Ph I/II POC trial ongoing in Greater China; (18) Ph Ib potentially registrational trial initiated in Greater China; (19) Global Ph I dose escalation ongoing, Ph I trial initiated in 2Q 2021; (20) Achieved proof of concept of Phase 1b study in October 2021.
Ongoing Clinical Trials
For more information about the above trials, please visit https://clinicaltrials.gov